John F. Harms

2.5k citations

32 papers · 1.6k indexed · h-index 20

Pharmacology top 2%
- Cholinesterase and Neurodegenerative Diseases 6
Molecular Biology top 10%
- Phosphodiesterase function and regulation 10
- Receptor Mechanisms and Signaling 8
Cellular and Molecular Neuroscience top 10%
- Neuroscience and Neuropharmacology Research 5
- Neuropeptides and Animal Physiology 3
Oncology top 10%
- Pancreatic and Hepatic Oncology Research 3
Reproductive Medicine top 10%
Epidemiology
- Neuroendocrine Tumor Research Advances 3
Physiology
- Nitric Oxide and Endothelin Effects 3

Co-authors: Danny R. Welch Christopher J. Schmidt Douglas S. Chapin Frank S. Menniti Sheryl A. McCarthy Judith A. Siuciak Lorraine A. Lebel Mary E. Miele
Cited by: Pharmacology Molecular Biology Cellular and Molecular Neuroscience
Journals: Journal of Neuroscience (1 paper)Biochemistry (1 paper)Cancer Research (1 paper)
Partner nations: United States Netherlands India

In The Last Decade

John F. Harms

32 papers receiving 1.6k citations

Peers

Countries citing papers authored by John F. Harms

Since Specialization

Citations

This map shows the geographic impact of John F. Harms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Harms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Harms more than expected).

Fields of papers citing papers by John F. Harms

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Harms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Harms. The network helps show where John F. Harms may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John F. Harms, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John F. Harms Line = papers co-authored together John F. Harms links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide Frontiers in Neuroscience ·John F. Harms,Frank S. Menniti,Christopher J. Schmidt	2019	21
2	Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A Translational Psychiatry ·Matthew S. Alexander,Molly Gasperini,Peter T. Tsai,Devin Gibbs,Janelle M. Spinazzola,Jamie L. Marshall,Michael Feyder,Mathew T. Pletcher,Eugene L. Piatnitski Chekler,Carl Morris,Mustafa Şahin,John F. Harms,C J Schmidt,Robin J. Kleiman,Louis M. Kunkel	2016	15
3	Facilitation of Corticostriatal Transmission following Pharmacological Inhibition of Striatal Phosphodiesterase 10A: Role of Nitric Oxide-Soluble Guanylyl Cyclase-cGMP Signaling Pathways Journal of Neuroscience ·Fernando E. Padovan‐Neto,Stephen Sammut,Shreaya Chakroborty,Alexander M. Dec,Sarah Threlfell,Peter W. Campbell,Vishnu Mudrakola,John F. Harms,Christopher J. Schmidt,Anthony R. West	2015	40
4	A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer Cancer Biology & Therapy ·Jill P. Smith,John F. Harms,Gail L. Matters,Christopher O. McGovern,Francesca Ruggiero,Jiangang Liao,Kristin Fino,Emily E. Ortega,Evan L. Gilius,John A. Phillips	2012	15
5	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 H -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). Journal of Medicinal Chemistry ·Patrick R. Verhoest,Douglas S. Chapin,Michael L. Corman,Kari R. Fonseca,John F. Harms,Xinjun Hou,Eric S. Marr,Frank S. Menniti,Frederick Nelson,Rebecca E. O’Connor,Jayvardhan Pandit,Caroline Proulx-LaFrance,Anne W. Schmidt,Christopher J. Schmidt,Judith A. Suiciak,Spiros Liras	2009	172
6	Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression Pancreas ·Gail L. Matters,John F. Harms,Christopher O. McGovern,Calpurnia Jayakumar,Keisha Crepin,Zachary P. Smith,Melissa C. Nelson,Heather Stock,Craig W. Fenn,James M. Kaiser,Mark Kester,Jill P. Smith	2009	28
7	Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters Substance P level Regulatory Peptides ·Nuray Erin,Güliz A. Barkan,John F. Harms,Gary A. Clawson	2008	63
8	The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease Journal of Immunotoxicology ·Gail L. Matters,John F. Harms,Christopher O. McGovern,Leo R. Fitzpatrick,Anuj Parikh,Nicholas Nilo,Jill P. Smith	2008	23
9	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt,Douglas S. Chapin,J. Cianfrogna,Michael L. Corman,Mihály Hajós,John F. Harms,William E. Hoffman,Lorraine A. Lebel,Sheryl A. McCarthy,Fredrick R. Nelson,Caroline Proulx-LaFrance,Mark J. Majchrzak,Andres D. Ramirez,Karl T. Schmidt,P A Seymour,Judith A. Siuciak,F. David Tingley,Robert D. Williams,Patrick R. Verhoest,Frank S. Menniti	2008	238
10	Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background Neuropharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,A. Martin,John F. Harms,Christopher J. Schmidt	2007	49
11	A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening Bioorganic & Medicinal Chemistry Letters ·John Lowe,Susan E. Drozda,Weimin Qian,Mark Peakman,J. Liu,John P. Gibbs,John F. Harms,Christopher Schmidt,Katherine Fisher,Christine A. Strick,Anne W. Schmidt,Michelle Vanase,Lorraine A. Lebel	2007	7
12	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis Neuropharmacology ·Judith A. Siuciak,Douglas S. Chapin,John F. Harms,Lorraine A. Lebel,Sheryl A. McCarthy,Leslie K. Chambers,Alka Shrikhande,Stephen K.-F. Wong,Frank S. Menniti,Christopher J. Schmidt	2006	226
13	MDA-MB-435 human breast carcinoma metastasis to bone Clinical & Experimental Metastasis ·John F. Harms,(unknown)	2003	52
14	KISS1 metastasis suppression and emergent pathways Clinical & Experimental Metastasis ·John F. Harms,Danny R. Welch,Mary E. Miele	2003	88
15	Maintaining GFP Tissue Fluorescence through Bone Decalcification and Long-Term Storage BioTechniques ·John F. Harms,Lynn R. Budgeon,Neil D. Christensen,Danny R. Welch	2002	21
16	Analysis of mechanisms underlying BRMS1 suppression of metastasis Clinical & Experimental Metastasis ·Rajeev S. Samant,M. Jabed Seraj,Margaret Saunders,Toshiyuki Sakamaki,Lalita A. Shevde,John F. Harms,Timothy O. Leonard,Steven F. Goldberg,Lynn R. Budgeon,William J. Meehan,Cathy R. Winter,Neil D. Christensen,Michael F. Verderame,Henry J. Donahue,Danny R. Welch	2000	94
17	Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate Clinical & Experimental Metastasis ·Steven F. Goldberg,John F. Harms,Kim Quon,Danny R. Welch	1999	71
18	A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat Journal of neurosurgery ·Eiji Tsuchida,John F. Harms,John J. Woodward,Ross Bullock	1996	26
19	Potentiation of N‐Methyl‐d‐Aspartate‐Stimulated Dopamine Release from Rat Brain Slices by Aluminum Fluoride and Carbachol Journal of Neurochemistry ·John J. Woodward,John F. Harms	1992	11
20	The putative polyamine antagonists ifenprodil and SL 82.0715 enhance dopamine efflux from rat striatal slices independent of NMDA receptor activation European Journal of Pharmacology ·John J. Woodward,John F. Harms	1992	13

About John F. Harms

John F. Harms is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Molecular Biology, having authored 32 papers that have together received 1.6k indexed citations. Recurring topics across this work include Phosphodiesterase function and regulation (10 papers), Receptor Mechanisms and Signaling (8 papers), Cholinesterase and Neurodegenerative Diseases (6 papers), Neuroscience and Neuropharmacology Research (5 papers), Neuroendocrine Tumor Research Advances (3 papers), Nitric Oxide and Endothelin Effects (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Neuropeptides and Animal Physiology (3 papers). The work is most often cited by research in Pharmacology (450 citations), Molecular Biology (1.2k citations) and Cellular and Molecular Neuroscience (267 citations). John F. Harms has collaborated with scholars based in United States, Netherlands and India. Frequent co-authors include Danny R. Welch, Christopher J. Schmidt, Douglas S. Chapin, Frank S. Menniti, Sheryl A. McCarthy, Judith A. Siuciak, Lorraine A. Lebel, Mary E. Miele, Steven F. Goldberg and Patrick R. Verhoest. Their work appears in journals such as Journal of Neuroscience, Biochemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact